Product
Xanomeline + Trospium Chloride
Aliases
KarXT, Xanomeline and Trospium Chloride Capsules
6 clinical trials
1 indication
Indication
SchizophreniaClinical trial
A Phase 3, Multicenter, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 SchizophreniaStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaStatus: , Estimated PCD: 2026-02-01
Clinical trial
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 SchizophreniaStatus: Completed, Estimated PCD: 2022-05-24
Clinical trial
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 SchizophreniaStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 SchizophreniaStatus: Completed, Estimated PCD: 2022-11-29
Clinical trial
A Multi-center, Open-label Study to Assess the Effectiveness, Long-term Safety, Tolerability, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of SchizophreniaStatus: Terminated, Estimated PCD: 2023-03-01